Feed MRK
MR

Merck & Co.

MRK · NYSE

$143.80 -0.72% (-$1.05)
1M +5.85%
Market Cap $357.7B
P/E Ratio 112.74x
Div. Yield 2.35%
ROE 6.60%

Bulios Fair Price

$141.35

1.7% downside

Trenutna cena

$143.8

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price se delnica MRK trenutno trguje blizu svoje poštene vrednosti. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Moderate
5/9
Valuation
22 /100
Expensive
P/E 112.74x
P/FCF 22.27x
EV/EBITDA 29.24x
Growth
34 /100
Stable
EPS growth 8.43%
Book val. growth 4.58%
Rev. growth 3.08%
Profitability
78 /100
Strong
Gross margin 75.38%
FCF margin 24.19%
Net margin 4.78%
Quality
31 /100
Poor
ROIC 5.62%
Asset turnover 0.51x
ROE 6.60%
Debt
46 /100
Moderate
Debt/Equity 1.29x
Net debt/EBITDA 3.40x
Current ratio 1.32x
Stability
47 /100
Moderate
Beta 0.23x
Profitable years 6
Rev. volatility 3.15%

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o MRK
Online

O podjetju

Merck & Co., Inc. (MRK) is a global pharmaceutical company with a long history and a broad portfolio of medicinal products. The company focuses on research, development, and manufacturing of drugs and biologics for various diseases, including cardiovascular diseases, oncological conditions, infectious diseases, diabetes, and other serious health conditions. Merck & Co. is known for its innovative pharmaceutical products, which are developed with an emphasis on safety and efficacy. The company has a strong research team that focuses on discovering new drugs and therapeutic approaches. Merck & Co. also collaborates with academic institutions and scientific partners to advance medicines and biotechnologies. The company has a global presence, and its products are distributed worldwide. Merck & Co., Inc. (MRK) shares are an attractive choice for investors who follow the pharmaceutical industry and seek investment opportunities in an established and innovative pharmaceutical company.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Robert Davis

Employees

74,000

Headquarters

Rahway

Prihajajoči dogodki

29 OKT.

Earnings

Upcoming earnings report

43d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.